Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
She was not full time at Stratex, and in any case she effectivley gained full control of Goldstone from the bunch of useless old duffers running the (part) owner for next to nothing and sorted out the vast array of issues that were blocking progress. I don't like to see operational issues but its a fact of life in gold mining, just don't forget that bigger mountains were climbed just to get to this stage.
Again, the emotional connection to gold. BTC outperformed every assets class for YEARS on end and still some folk cling to the past. Sure hold some gold or gold projects as diversification but if you aren't in cryptos, especially payments and DeFi, you are being irresponsible with your portfolio. Gold should be on an absolute tear but it isn't because of the movement from gold into cryptos.
Sorry but the fact your are speaking of BTC when alt season started shows that you are best staying will away from cryptos. IF you want to make SERIOUS money it will be in the altcoins. Bitcoin cash and XRP in particular show potential for massive % gains. As always with cryptos, just as with crappy penny stocks, only invest what you can afford to lose, and preferably remove your original capital at the earliest opportunity if you want to play extra safe.
These small goldies are all about the people in charge. The rest barely matters. You can have an excellent gold facility in, let's say Turkey for example, and end up with it being worth barely anything due to the extraordinary incompetence of a bunch of old fools running the show. Emma Priestly and her team are top rank and meeting her briefly was enough to cause me to dump my entire Stratex holding and move it to Goldstone.
But it isn't ask if GSK is helpless in this, they have a whole fx team in finance to mitigate currency fluctuations over the long term, it's not like they immediately convert USD -> GBP at the most derisory rate available at any given time. Hard to believe this was 1850 not so long ago.
As a global leader in vaccines, GSK's partnership with Sanofi , and other partnerships with biotech partners like Vir, stand the best chance of an effective, safe vaccine manufactured at industrial scale based on proven technology . Why then is GSK well down YTD while others are up 5-35%? So much buzz about the experimental Oxford vaccine that vaccine giants wouldn;t touch. There's a reason why AZ, with zero vaccine experience, was left to partner with Oxford after no one else would touch it.
Occidental's minority stake in both Jubilee (21kbpd) and TEN (8kbpd) iirc are up for sale again following Total's waiver. I guess Tullow must be looking at these given that it is the operator, but I have no idea how they would pay for it.
I agree production on Jubilee is now excellent. But production is TEN is a shameful disaster and remains an urgent issue that the new CEO must grapple with. They need an extensive work programme in 2021 to compensate for the crappy Enyenra wells and get that production back up towards 100kbpd where it actually constitutes a viable business.
What always bothered me about Dot's forward guidance, and believe me I have had almost tearful exchanges with IR folk on this matter, no joke, is that they were guiding for 150kbpd as recently as late 2018 and now they are talking about just 70kbpd while running at 76kbpd currently and still be guarded over the details of how much of the benefit of the 2020 work programme is included in this forecast. If I was not so depressed about the whole thing I honestly cannot help wondering if the police should 'avin words with McDade as you cannot simply dismiss this as "bad forecasting".
Do we know for a fact that Ntomme-9 is delayed? To date I have been told there has been no impact of activities in Ghana. What hasn't been made clear is if production from Ntomme-9 is factored into the c70kbpd forecast for 2021. In the absence of further information I have to assume it is. What makes little sense though is that with production running at 76kbpd and all the work programme activity this year, what underlies their assumption for the large 5kbpd decline to arrive at their 2021 forecast numbers?
AZN are doing well, why mess it up with an expensive acquisition only made possible by the recent increase in market cap? Gilead itself is very over priced right now makimg talk of buyout even less attractive. These huge corporate actions rarely benefit shareholders of the aquirer, just line bankers pockets and payouts for the board. Why not increase the dividend instead?